The Zacks Analyst Blog Eli Lilly, Medtronic, Intuitive Surgical, Regeneron Pharmaceuticals and Johnson & Johnson
View original at finance.yahoo.comThe Zacks Analyst Blog Eli Lilly, Medtronic, Intuitive Surgical, Regeneron Pharmaceuticals and Johnson & Johnson For Immediate Releases Chicago, IL – January 6, 2026 – Zacks.com announces the list of stocks featured in the Analyst Blog…
What we drew from this source
The claims Via News extracted from this document. We point to the source; we don't replace it.
Medtronic carries a Zacks Rank #2 (Buy)
80% confidenceJohnson & Johnson has an expected earnings growth rate of 5.7% for the current year
80% confidenceZacks top stock-picking strategies soared with average gains of +48.4%, +50.2% and +56.7% per year since 2000
80% confidenceEli Lilly has an expected earnings growth rate of 41.3% for the current year
80% confidenceMedtronic has an expected revenue growth rate of 7.5% for the current year (ending April 2026)
80% confidenceRegeneron Pharmaceuticals has an expected revenue and earnings growth rate of 4.9% and -0.4%, respectively, for the current year
80% confidenceThe healthcare sector is generally defensive in nature with most stocks characterized as low-beta and dividend paying, but extensive use of AI has transformed several into potential high-growth providers
80% confidenceJNJ has an ROE of 32.7% compared with the industry's ROE of 37% and the S&P 500's ROE of 17%
80% confidenceThe supercomputer will power an AI factory, a specialized computing infrastructure that manages the entire AI lifecycle from data ingestion and training to fine-tuning and high-volume inference.
80% confidenceMDT has an ROE of 14.9% compared with the industry's ROE of -2.5% and the S&P 500's ROE of 17%
80% confidenceIntuitive Surgical carries a Zacks Rank #2 (Buy)
80% confidenceRegeneron carries a Zacks Rank #2
80% confidenceEli Lilly has a return on equity of 109.5% compared with the industry's ROE of 37% and the S&P 500's ROE of 17%
80% confidenceIntuitive Surgical carries a Zacks Rank #2
80% confidenceIntuitive Surgical has an expected earnings growth rate of 11.1% for the current year
80% confidenceRegeneron Pharmaceuticals has an expected revenue growth rate of 4.9% for the current year
80% confidenceThe Zacks Consensus Estimate for Eli Lilly current-year earnings has improved 0.7% over the last 30 days
80% confidenceRegeneron Pharmaceuticals carries a Zacks Rank #2 (Buy)
80% confidenceHypertension presents a multi-billion-dollar opportunity as Medtronic ramps up for CMS coverage of Symplicity
80% confidenceAI fundamentally reshaped the medical landscape in 2024, revolutionizing diagnostics, treatment and operational efficiency
80% confidenceRegeneron Pharmaceuticals has an expected earnings growth rate of -0.4% for the current year
80% confidenceRegeneron put up a decent performance in 2025 as revenues grew despite declining sales of its lead drug Eylea
80% confidenceThe medical sector is one of the major adopters of artificial intelligence, which is currently being used to synthesize new compounds for drugs and create devices for more precise measurement and faster as well as more accurate diagnosis
80% confidenceMedtronic currently carries a Zacks Rank #2 (Buy)
80% confidenceEli Lilly has an expected revenue growth rate of 22.3% for the current year
80% confidenceIntuitive Surgical has an expected revenue growth rate of 14.3% for the current year
80% confidenceAI fundamentally reshaped the medical landscape in 2024, revolutionizing diagnostics, treatment and operational efficiency
80% confidenceThe supercomputer will power an AI factory, a specialized computing infrastructure that manages the entire AI lifecycle from data ingestion and training to fine-tuning and high-volume inference
80% confidenceEli Lilly has an expected revenue and earnings growth rate of 22.3% and 41.3%, respectively, for the current year
80% confidenceMedtronic has an expected revenue and earnings growth rate of 7.5% and 2.7%, respectively, for the current year ending April 2026
80% confidence